DDOG vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Datadog, Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
Datadog, Inc. · Technology
$256.92
+28.7% upside to fair value
Med Conviction
Grade C
High Quality
VS
Johnson & Johnson · Healthcare
$270.68
+5.7% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
DDOG has more upside to fair value
(+28.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DDOG |
JNJ |
| Current Price |
$256.92 |
$270.68 |
| Fair Value Estimate |
$330.72 |
$286.05 |
| Upside to Fair Value |
+28.7%
|
+5.7%
|
| Market Cap |
$91.5B |
$652.3B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
350.6x
|
20.2x
|
| Price / Sales |
23.1x
|
6.7x
|
| Price / FCF |
78.9x
|
35.3x
|
| Revenue Growth YoY |
+35.6%
|
+6.6%
|
| Gross Margin |
79.5%
|
67.9%
|
| Operating Margin |
0.4%
|
26.8%
|
| Return on Equity |
4.6%
|
25.7%
|
| Dividend Yield |
0% |
1.95% |
| FCF Yield |
1.27%
|
2.83%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Datadog is a cloud observability platform that unifies infrastructure monitoring, application performance management, log management, security, and incident response into a single SaaS offering used by developers and IT operations teams across North America and internationally. The business quality is high on the top line: revenue grew 35.6% year over year in the most recent quarter, TTM gross ma…
Johnson & Johnson is a 141,700-employee healthcare holding company operating two segments, Innovative Medicine (immunology, oncology, neuroscience, infectious disease, cardiovascular and metabolism, pulmonary hypertension) and MedTech (interventional solutions, orthopaedics, surgery, vision), founded in 1887 and headquartered in New Brunswick, New Jersey. Business quality is high on fundamentals:…
Accumulation Zones
| Metric |
DDOG |
JNJ |
| Zone Low |
$248.04 |
$214.54 |
| Zone High |
$281.11 |
$243.14 |
| In Buy Zone? |
Yes
|
No
|